Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
137.8 ^USD	-0.87%		+3.94%	+4.55%

Apr. 24	Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	MT
Apr. 24	Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	CI

Neurocrine Biosciences, Inc. Appoints Jude Onyia, Ph.D., as Chief Scientific Officer

November 30, 2021 at 04:05 pm EST

Neurocrine Biosciences, Inc. announced that Jude Onyia, Ph.D., has joined the company's executive management team as Chief Scientific Officer.

Latest news about Neurocrine Biosciences, Inc.

Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170	Apr. 24	MT
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	Apr. 24	CI
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	Apr. 23	CI
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	Apr. 16	MT
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development	Apr. 16	MT
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	Apr. 16	CI
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept	Apr. 08	MT
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study	Apr. 03	MT
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	Apr. 03	CI
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug	Mar. 28	MT
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	Mar. 28	CI
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating	Mar. 20	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 02:00 PM	Mar. 19
Transcript : Neurocrine Biosciences, Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:00 PM	Mar. 18
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing	Mar. 15	MT
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing	Mar. 15	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM	Mar. 13
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating	Mar. 13	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	Mar. 12
Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM	Mar. 05
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing	Mar. 01	MT
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing	Mar. 01	MT
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Feb. 26	CI
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing	Feb. 22	MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating	Feb. 20	MT

Chart Neurocrine Biosciences, Inc.

Duration

Period

More charts

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Neurocrine Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

137.8 USD

Average target price

153.6 USD

Spread / Average Target

+11.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B
LEGEND BIOTECH CORPORATION	-26.18%	8.22B

Bio Therapeutic Drugs